These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 7547242)

  • 1. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
    Negri DR; Tosi E; Valota O; Ferrini S; Cambiaggi A; Sforzini S; Silvani A; Ruffini PA; Colnaghi MI; Canevari S
    Br J Cancer; 1995 Oct; 72(4):928-33. PubMed ID: 7547242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients.
    Tibben JG; Boerman OC; Massuger LF; Schijf CP; Claessens RA; Corstens FH
    Int J Cancer; 1996 May; 66(4):477-83. PubMed ID: 8635863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.
    Tosi E; Valota O; Negri DR; Adobati E; Mazzoni A; Meazza R; Ferrini S; Colnaghi MI; Canevari S
    Int J Cancer; 1995 Sep; 62(5):643-50. PubMed ID: 7665239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI; Nelson H; Thibault C
    J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells.
    Zhu Z; Lewis GD; Carter P
    Int J Cancer; 1995 Jul; 62(3):319-24. PubMed ID: 7628874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation.
    Ferrini S; Cambiaggi A; Sforzini S; Marciano S; Canevari S; Mezzanzanica D; Colnaghi MI; Grossi CE; Moretta L
    Int J Cancer; 1993 Dec; 55(6):931-7. PubMed ID: 8253530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
    Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH
    Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
    Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
    Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
    Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
    J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
    van Dijk J; Zegveld ST; Fleuren GJ; Warnaar SO
    Int J Cancer; 1991 Jul; 48(5):738-43. PubMed ID: 1830033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic.
    Mezzanzanica D; Canevari S; Colnaghi MI
    Int J Clin Lab Res; 1991; 21(2):159-64. PubMed ID: 1815760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.
    Mezzanzanica D; Garrido MA; Neblock DS; Daddona PE; Andrew SM; Zurawski VR; Segal DM; Wunderlich JR
    Cancer Res; 1991 Oct; 51(20):5716-21. PubMed ID: 1833054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab')2 derivative for recruitment of cytotoxic effectors.
    Greenman J; Tutt AL; George AJ; Pulford KA; Stevenson GT; Glennie MJ
    Mol Immunol; 1991 Nov; 28(11):1243-54. PubMed ID: 1835758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
    Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
    J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb.
    Hirsch R; Bluestone JA; DeNenno L; Gress RE
    Transplantation; 1990 Jun; 49(6):1117-23. PubMed ID: 2141740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
    Hirsch R; Archibald J; Gress RE
    J Immunol; 1991 Oct; 147(7):2088-93. PubMed ID: 1833451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.